Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
innovation tags : Antibody save search
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
Published: 2023-11-14 (Crawled : 06:00) - globenewswire.com
MOLN | News | $3.74 -3.54% 6.2K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
europe antibody protein molecular
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
Published: 2023-08-08 (Crawled : 03:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
ibi363 antibody cancer preclinical results
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
Published: 2023-01-20 (Crawled : 14:20) - biospace.com/
SMMT A | $3.51 0.0% 1.7M
|
Health Technology
|
| O: 2.36%
H: 5.08%
C: 1.39%
antibody deal therapeutics
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
Published: 2022-08-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.43%
H: 1.39%
C: 0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.16%
H: 0.56%
C: -0.19%
ibi363 australia antibody study phase 1
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ibi110 antibody
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.88%
H: 0.51%
C: -0.15%
ibi110 trials antibody
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
Published: 2022-04-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.36%
H: 0.24%
C: -0.62%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.52%
H: 1.58%
C: 0.22%
ibi310 treatment cancer designation antibody
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-03-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.13%
H: 0.38%
C: -1.25%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.05%
H: 1.43%
C: 1.01%
ibi389 trial antibody phase 1
BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies
Published: 2022-03-24 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
collaboration antibody therapy
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-23 (Crawled : 01:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.59%
H: 0.89%
C: -0.93%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.87%
H: 0.84%
C: -1.12%
cd73 trial phase 1 antibody phase 1b
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-24 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -1.25%
H: 1.21%
C: 1.04%
cd73 trial phase 1 antibody phase 1b
Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint
Published: 2022-02-17 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.72%
H: 2.03%
C: 0.73%
ibi306 antibody
BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany
Published: 2021-12-22 (Crawled : 12:30) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
covid-19 commercialization covid germany therapy antibody
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
Published: 2021-11-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.59%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 1.38%
H: 0.98%
C: -2.62%
results communication antibody communications preclinical pre-clinical
Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021
Published: 2021-09-29 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.19%
solid tumors results antibody her2+ her2- her2
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
Published: 2021-09-24 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
phase 2 antibody trial psoriasis plague
Innovent Announces IBI306 (anti-PCSK-9 antibody) Meets the Primary Endpoint in a Phase 3 Clinical Study for Chinese Heterozygous Familial Hypercholesterolemia
Published: 2021-08-12 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.34%
H: 0.51%
C: 0.1%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.55%
H: 0.2%
C: -0.55%
chinese antibody phase 3 hypercholesterolemia
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-26 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.53%
H: 1.12%
C: 0.26%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.49%
H: 0.51%
C: -1.85%
phase 1 antibody phase 2
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
phase 1 antibody phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
RC | $8.62 1.77% 0.81% 1M
|
Finance
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.